This meeting took place in 2018
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Progress and Pathways Toward an Effective HIV Vaccine (J6)
Organizer(s) M. Juliana McElrath, Pamela J. Bjorkman and Beatrice H. Hahn
January 28—February 1, 2018
Fairmont Banff Springs • Banff, AB Canada
Discounted Abstract Deadline: Oct 4, 2017
Abstract Deadline: Nov 2, 2017
Scholarship Deadline: Oct 4, 2017
Discounted Registration Deadline: Dec 6, 2017
Sponsored by Pfizer Inc.
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation
Summary of Meeting:
After three decades, HIV-1 continues to afflict and kill millions of people worldwide. A safe and effective vaccine that elicits potent and durable protective immunity has the greatest prospect to end the AIDS epidemic. Development of an HIV vaccine has proven scientifically challenging, as evidenced by only one weakly efficacious regimen after evaluation of four distinct regimens. However, the field is in a phase of rapid growth and innovation for new vaccine strategies that hold promise for efficacy. Such emerging, novel findings will be the focus of this meeting, and will include: 1) Technological advances in structural properties of the HIV-1 envelope glycoprotein and its recognition and interactions with potent neutralizing antibodies; 2) Improved animal model platforms that can better mimic the transmitted founder HIV-1 strains and human immune recognition; 3) Greater understanding of host B and T cell immunobiology in the lymphoid germinal centers that is critical to optimize candidate vaccines and immunization regimens; 4) New tools for interrogating human immune repertoire; and 5) highlights of promising strategies in first in human to efficacy studies. Emphasis will be placed on unpublished findings and advances specifically relevant to human immunology and HIV vaccine targets.
View Meeting Program
After three decades, HIV-1 continues to afflict and kill millions of people worldwide. A safe and effective vaccine that elicits potent and durable protective immunity has the greatest prospect to end the AIDS epidemic. Development of an HIV vaccine has proven scientifically challenging, as evidenced by only one weakly efficacious regimen after evaluation of four distinct regimens. However, the field is in a phase of rapid growth and innovation for new vaccine strategies that hold promise for efficacy. Such emerging, novel findings will be the focus of this meeting, and will include: 1) Technological advances in structural properties of the HIV-1 envelope glycoprotein and its recognition and interactions with potent neutralizing antibodies; 2) Improved animal model platforms that can better mimic the transmitted founder HIV-1 strains and human immune recognition; 3) Greater understanding of host B and T cell immunobiology in the lymphoid germinal centers that is critical to optimize candidate vaccines and immunization regimens; 4) New tools for interrogating human immune repertoire; and 5) highlights of promising strategies in first in human to efficacy studies. Emphasis will be placed on unpublished findings and advances specifically relevant to human immunology and HIV vaccine targets.
View Meeting Program
Scholarships/Awards
National Institute of Allergy and Infectious Diseases (NIAID) Scholarship Recipients
Omolara Olujimi Baiyegunhi
University of KwaZulu-Natal, South Africa
Christopher O. Barnes
California Institute of Technology, USA
Sushma Boppana
University of Alabama at Birmingham, USA
Kimberly M. Cirelli
La Jolla Institute for Immunology, USA
Christopher A. Cottrell
The Scripps Research Institute, USA
Allen Lin
Harvard University, USA
Matthias Georg Pauthner
The Scripps Research Institute, USA
Daniel Reeves
Fred Hutchinson Cancer Research Center, USA
Jonathan Richard
Centre de Recherche du CHUM, Canada
Marlies Melanie Van Haaren
Amsterdam University Medical Center, Netherlands
Chengcheng Zou
Center for AIDS Research, Kumamoto University, Japan
Keystone Symposia Global Health Travel Award Recipients, funded by the Bill & Melinda Gates Foundation
Olutoyin Omolara Bamigboye
Adeleke University, Nigeria
Lavinia Joy Muyoti Bwisa
Jomo Kenyatta University of Agriculture and Technology, Kenya
Rajat Desikan
Indian Institute of Science, India
Martin Ositadinma Ifeanyichukwu
Nnamdi Azikiwe University, Nigeria
Samuel Mundia Kariuki
University of Cape Town, South Africa
Christopher Kintu
Makerere University School of Medicine, Uganda
Dale Kitchin
National Institute for Communicable Diseases, South Africa
Enoch Sekayita Muyanja
Uganda Virus Research Institute-International AIDS Vaccine Initiative, Uganda
Sylvia Nanono
MRC/UVRI Uganda Research Unit on AIDS, Uganda
Amobi Emmanuel Nwakaeze
Ebonyi State University, Nigeria
Borna Achieng Nyaoke
Kenya AIDS Vaccine Initiative, Kenya
Simone Irene Richardson
National Institute for Communicable Diseases, South Africa
Shariq Mahmood Usmani
Massachusetts General Hospital, USA
Qian Wang
Tsinghua University, China
